Isolation and characterization of a novel liver-derived immunoinhibitory factor

Authors

  • Shie-Pon Tzung,

    1. Department of Medicine, Division of Gastroenterology and Hepatology, Veterans Administration Medical Center and Buffalo General Hospital, State University of New York at Buffalo, School of Medicine and Biomedical Sciences, Buffalo, New York 14215
    Current affiliation:
    1. Department of Medicine, Duke University Medical Center, Durham, NC 27710
    Search for more papers by this author
  • Katherine C. Gaines,

    1. Department of Medicine, Division of Gastroenterology and Hepatology, Veterans Administration Medical Center and Buffalo General Hospital, State University of New York at Buffalo, School of Medicine and Biomedical Sciences, Buffalo, New York 14215
    Search for more papers by this author
  • Mark Henderson,

    1. Department of Medicine, Division of Gastroenterology and Hepatology, Veterans Administration Medical Center and Buffalo General Hospital, State University of New York at Buffalo, School of Medicine and Biomedical Sciences, Buffalo, New York 14215
    Search for more papers by this author
  • Terry J. Smith,

    1. Department of Medicine, Division of Endocrinology, Veterans Administration Medical Center and Buffalo General Hospital, State University of New York at Buffalo, School of Medicine and Biomedical Sciences, Buffalo, New York 14215
    Current affiliation:
    1. Division of Cellular and Molecular Medicine, Department of Medicine, Albany Medical College, Albany, NY 12208
    Search for more papers by this author
  • Stefan A. Cohen Ph.D.

    Corresponding author
    1. Department of Medicine, Division of Gastroenterology and Hepatology, Veterans Administration Medical Center and Buffalo General Hospital, State University of New York at Buffalo, School of Medicine and Biomedical Sciences, Buffalo, New York 14215
    • Division of Gastroenterology, Veterans Administration Medical Center, 3495 Bailey Ave., Buffalo, NY, 14215
    Search for more papers by this author

Abstract

Cytosolic extracts prepared from perfused whole liver or purified hepatocytes of C57BL/6 mice inhibited interleukin-2– and concanavalin A–induced spleen cell proliferation in vitro. In contrast, cytosolic extracts from purified nonparenchymal liver cells had no effect. Arginase and very-low-density lipoprotein were previously identified as two immunoinhibitory substances present in liver cytosolic extracts. We demonstrated, however, that inhibitory activity remained after removal of very-low-density lipoprotein and arginase from liver cytosolic extract by repeated ultracentrifugation and gel filtration chromatography, respectively, suggesting the presence of another inhibitor. Further purification by anion-exchange chromatography and chromatofocusing led to the isolation of a novel liverderived immunoinhibitory factor. This liver-derived immunoinhibitory factor is sensitive to pronase digestion and heat and acid treatment; it has an estimated isoelectric point of 8.25. The Mr of liver-derived immunoinhibitory factor is 28 kD as estimated from its migration on sodium dodecyl sulfate–polyacrylamide gel electrophoresis, which is identical under both reducing and nonreducing conditions, indicating a monomeric nature of this protein. Amino acid composition analysis discloses that liver-derived immunoinhibitory factor is relatively rich in glycine and proline residues. Interleukin-2–induced spleen cell proliferation in vitro is inhibited by this liver-derived immunoinhibitory factor, with a 50% inhibitory dose of 1.4 nmol/L. Furthermore, the biological activity of the liver-derived immunoinhibitory factor is not confined to mouse spleen cells, since the growth of B16 mouse melanoma and H35 rat hepatoma cells is also inhibited. A comparison with other liver-derived immunoinhibitors reported previously supports our claim that the liver-derived immunoinhibitory factor is a novel inhibitory protein. (HEPATOLOGY 1991;14:888–894).

Ancillary